Neurological disorders are among the greatest healthcare challenges of our time. Alzheimer's. Parkinson's. Stroke. Multiple sclerosis. These conditions affect hundreds of millions of people globally — and prevalence is rising as the world's population ages.
That's why the neuroprotective agents market is one of the largest and most actively invested therapeutic segments in pharmaceuticals. Valued at $41.2 billion in 2024, it's projected to reach $60.9 billion by 2030 at a 6.7% CAGR.
The growth drivers are powerful and compounding. The global burden of neurological disease continues to expand. Aging populations are driving higher prevalence of neurodegenerative conditions. And recent breakthroughs — particularly in Alzheimer's disease therapeutics — have reinvigorated pipeline activity and investor confidence.
North America leads with 41.4% of the market. The competitive landscape reads like a who's who of big pharma: AbbVie, Biogen, Roche, Lilly, Novartis, Bristol-Myers Squibb and more. But the real innovation frontier is in emerging therapeutic modalities — gene therapy, stem cell approaches, nanotechnology-based drug delivery and precision medicine.
The risks are well-known: clinical trial failure rates in neuroscience remain high, and development costs are substantial. But for the companies that succeed, the commercial prize is enormous.
Curious about the pipeline, competitive landscape and emerging technologies? Download the free overview of our report Neuroprotective Agents: Therapeutic Applications and Global Markets for the complete market analysis.
Download the Free Report Overview →